| Trial ID: | L6479 |
| Source ID: | NCT00231387
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Non-insulin-dependent Diabetes Mellitus
|
| Interventions: |
DRUG: rosiglitazone
|
| Outcome Measures: |
Primary: The effect of 52 wks oral treatment with rosiglitazone in comparison to placebo on change from baseline of the plaque total wall volume in the carotid artery, in patients with type 2 dm and vascular disease/hypertension, using cardiac mri., 52 Weeks | Secondary: These include magnetic resonance endpoints related to plaque lipid content, volume, plaque size and fibrous cap thickness. Colour duplex measurements, laboratory assays for glycaemia and lipids.
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-09
|
| Completion Date: |
2005-05
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-23
|
| Locations: |
GSK Clinical Trials Call Center, London, W2 1NY, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00231387
|
